Sonus Pharmaceuticals and OncoGenex Technologie...(DA submission; - OGX-427 is designe...)

- OGX-427 is designed to reduce production of Hsp27, a protein that is

over-produced in response to many cancer treatments including hormone

ablation therapy, chemotherapy and radiation therapy. OGX-427 is in a

Phase 1 clinical trial for the treatment of solid tumors including

prostate, non-small cell lung, breast, ovarian, and bladder cancers.

The company anticipates that the single-agent aspect of this trial

will be completed in the second half of 2008, and Phase 2 clinical

development will begin in 2009. Like OGX-011, this product candidate

has potential as a treatment in a broad number of cancers;

- SN2310 is a novel prodrug of SN-38, which is a potent anti-cancer

drug belonging to the class of topoisomerase I inhibitors. It is

currently in a Phase 1 trial and progress is being made to determine

its safety and pharmacokinetic profile, in addition to the maximum

tolerated dose. SN2310 is designed to enhance the delivery and

exposure of SN-38 to the tumor by providing greater prodrug

conversion and a longer half-life than achieved with irinotecan; and

- OGX-225 aims to reduce the production of both Insulin-Like Growth

Factor Binding Protein -2 and Insulin-Like Growth Factor Binding

Protein -5 with a single product to enhance treatment sensitivity and

delay tumor progression. IGFBP-2 and IGFBP-5 are both hormones that

make an alternate hormone, IGF-1, available to the tumor that

facilitates continued tumor growth. Employing OGX-225 as a single

product to simultaneously inhibit the production of both IGFBP-2 and

IGFBP-5 has the potential to delay disease progression in cancers

dependent upon IGF-1 for tumor growth. OGX-225 is in pre-clinical

development and has completed pre-clinical pharmacology. <
'/>"/>